The most commonly reported ocular side effect was stinging and burning.
BETIMOL® is contraindicated in patients with overt heart failure, cardiogenic shock, sinus bradycardia, second- or third-degree atrioventricular block, bronchial asthma or history of bronchial asthma, severe chronic obstructive pulmonary disease, or hypersensitivity to any component of this product.
BETIMOL® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
© VISTAKON® Pharmaceuticals, LLC.
This site is published by VISTAKON® Pharmaceuticals, LLC, which is solely responsible for its content.
It is intended for use by residents of the United States.
BETIMOL® is a registered trademark of Santen Pharmaceutical Co., LTD., and marketed by VISTAKON® Pharmaceuticals, LLC.
VISTAKON® is a registered trademark of VISTAKON® Pharmaceuticals, LLC.
Last Modified: 07/01/13